Kura Oncology (KURA) Stock Price, News & Analysis

Company Overview

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $15.44 to $16.09
• 50-Day Range: $15.91 to $21.08
• 52-Week Range: $9.06 to $24.17
• Volume: 904,670 shs
• Average Volume: 893,680 shs
• Market Capitalization: $1.24 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.83
• Consensus Rating: Buy

Kura Oncology Stock Analysis - MarketRank™

Kura Oncology scored higher than 82% of companies evaluated by MarketBeat, and ranked 183rd out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Kura Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Kura Oncology has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kura Oncology are expected to decrease in the coming year, from ($2.46) to ($2.72) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kura Oncology is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kura Oncology is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kura Oncology has a P/B Ratio of 2.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.39% of the float of Kura Oncology has been sold short.

Short Interest Ratio / Days to Cover

Kura Oncology has a short interest ratio ("days to cover") of 20.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Kura Oncology has recently increased by 16.25%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kura Oncology does not currently pay a dividend.

Dividend Growth

Kura Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.76

Percentage of Shares Shorted

16.39% of the float of Kura Oncology has been sold short.

Short Interest Ratio / Days to Cover

Kura Oncology has a short interest ratio ("days to cover") of 20.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Kura Oncology has recently increased by 16.25%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.48

News Sentiment

Kura Oncology has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Kura Oncology this week, compared to 5 articles on an average week.

Search Interest

2 people have searched for KURA on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Kura Oncology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Kura Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,432.00 in company stock.

Percentage Held by Insiders

Only 5.50% of the stock of Kura Oncology is held by insiders.

KURA Stock Analysis - Frequently Asked Questions

How have KURA shares performed this year?

Kura Oncology's stock was trading at $14.38 at the beginning of the year. Since then, KURA stock has increased by 10.6% and is now trading at $15.91.
View the best growth stocks for 2024 here.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) announced its earnings results on Thursday, August, 8th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.04. The business's revenue for the quarter was up .0% compared to the same quarter last year.

When did Kura Oncology's stock split?

Kura Oncology shares reverse split before market open on Friday, October 18th 2024. The 1-35 reverse split was announced on Monday, October 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are Kura Oncology's major shareholders?

Top institutional shareholders of Kura Oncology include Suvretta Capital Management LLC (9.84%), State Street Corp (3.43%), Geode Capital Management LLC (2.29%) and Assenagon Asset Management S.A. (1.38%). Insiders that own company stock include Thomas Malley, Teresa Brophy Bair, Thomas James Doyle, Kathleen Ford, Kirsten Flowers, Troy Edward Wilson, Anthony Scott Praill, Laura L Johnson and Saiid Zarrabian.
View institutional ownership trends.

How do I buy shares of Kura Oncology?

Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kura Oncology investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Walmart (WMT).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/25/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KURA
• CUSIP: N/A
• CIK: 1422143
• Web: www.kuraoncology.com
• Phone: (858) 500-8800
• Fax: N/A
• Employees: 142
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $28.83
• High Stock Price Target: $37.00
• Low Stock Price Target: $19.00
• Potential Upside/Downside: +81.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-152,630,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -44.09%
• Return on Assets: -39.57%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 11.47
• Quick Ratio: 11.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.35 per share
• Price / Book: 2.97

Miscellaneous

• Outstanding Shares: 77,760,000
• Free Float: 73,487,000
• Market Cap: $1.24 billion
• Optionable: Optionable
• Beta: 0.86